Skip to main content
Sign In


Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.


Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
Page Size
 |  Displaying page 1 of 5, items 1 to 30 of 121.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
Page Size
 |  Displaying page 1 of 5, items 1 to 30 of 121.
Brown Adipose Tissue and Estrogen (BATE Study) 13-0149
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
PI: Melanson, Edward
  • 720-848-6399
Type 2 Diabetes and Exercise Research Study 11-0909
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
PI: Huebschmann, Amy
  • 303-724-2255
Is your child 6-18 years old and interested in participating in a research study? 13-2073
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
PI: Jablonski, Kristin
  • 303-724-7791
Participants Ages 12-15 years old Needed for Research Study 04-0311
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
PI: Levisohn, Paul
  • 720-777-8608
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls 13-2927
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years


A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
PI: Miravalle, Augusto
  • 303-724-8388
Healthy Hispanic Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity.
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions or permanent metal implants or braces/retainers and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
Participants Needed for an Exercise Study for People with Multiple Sclerosis 14-0295
Researchers from the Neurophysiology of Movement Laboratory on the University of Colorado Boulder campus and the Multiple Sclerosis Center on the University of Colorado Anschutz Medical Campus are conducting a study to investigate the capacity of neuromuscular electrical stimulation to improve walking in persons with multiple sclerosis.
-Between 18 to 55 years of age -Have clinically confirmed diagnosis of MS -Are able to talk but have some difficulty walking
PI: Enoka, Roger
  • 303-724-4644
HIV-V-A004 - Learn More About A Clinical Research Study For Investigational HIV Vaccines. 14-2056
The purpose of this study is to assess the safety and immune system response to investigational HIV vaccines in healthy, HIV-uninfected adult volunteers. These assessments will help researchers plan future vaccine studies.
- Willing to participate and who understand the purpose and procedures of the study „- 18 – 50 years of age „- HIV-uninfected „- In good health „- Willing to maintain behavior consistent with low risk HIV exposure
PI: Campbell, MD, Thomas
  • 303-724-0801
Healthy Adolescents Needed 07-0709
Psychological study on how flexible your brain can shift from one task to another.
-Female -age 12-17 years old -in good health -on no medication
PI: Frank, Guido
  • 720-777-4026
Help test a mobile app for postpartum moms 14-1173
This research study will test a mobile application to learn more about how to best deliver information about diet and physical activity for postpartum women at elevated risk for diabetes and heart disease.
You may qualify for this study if you:  Are between 18-45 years old  Are in your third trimester of pregnancy or have given birth in the last 24 weeks  Have a postpartum BMI: 25-45 kg/m2  Have access to and be willing to use a wi-fi enabled iPhone or an iPod  Have a history of one or more of the following complications in your most recent pregnancy: o Gestational diabetes mellitus o Preeclampsia o Gestational hypertension o Pre-term delivery (32-37) weeks o Small for gestational age (
PI: Nicklas , Jacinda
  • 303-724-8898
Type 1 Diabetes Research Study 11-0649
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
PI: Schauer, Irene
  • 720-848-6690
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • Brittany Kling
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
protein and infant growth: Do you have a child younger than 6 months 14-0139
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
PI: Krebs, Nancy
  • 303-724-3248
Volunteers Needed: Thinking and Memory in Parkinson's Disease 13-2724
This research study aims to better understand how changes in brain activity may be related to thinking problems in Parkinson's Disease and to determine whether, by stimulating certain areas, thinking and memory can be improved.
Person's with Parkinson's Disease with mild thinking and memory problems. Between 40-90 years old. No metal in your body. No implant. Not taking any medication to improve memory. Not taking stimulants or seizure medication.
PI: Kluger, Benzi
  • 303-724-5973
We are looking for volunteers to participate in an N.I.H. funded research study.
Children 12 years of age and older and non-smoking Adults who have mild to moderate asthma who are not currently taking inhaled steroid medication
PI: Martin, Richard
  • 303-398-1443
Do You or Someone You Know Suffer From Relapse Remitting Multiple Sclerosis (RRMS)? 13-2209
The University of Colorado Denver is conducting a clinical trial to evaluate the effectiveness, safety and tolerability of two doses of oral administration of laquinimod in subjects with Relapse Remitting Multiple Sclerosis (RRMS). Patients that suffer from RRMS may experience a gradual increase of their disability over time. The purpose of this study is to find out whether laquinimod is safe and effective in slowing the rate of disability progression.
-Between the ages of 18 and 55 -Have clinically confirmed diagnosis of Multiple Sclerosis (MS) with relapse onset disease or relapsing-remitting disease course -Have had at least one documented relapse within 12 months prior to starting this study -Have not been treated with Natalizumab (Tysabri) or Rituximab 2 years prior to starting this study
PI: Vollmer, Timothy
  • 303-724-6351
Sedentary Behavior Research Study 14-0429
This research study plans to learn more about how the time we spend seated affects your health
Healthy male and female Age: 19-45 With BMI: 27-33 you may check this at: Be seated more than 6hr/d Be physically active on less than 3-4 days/wk
PI: Bergouignan, Audrey
  • 303-724-9026
Healthy Minority Volunteers Needed 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
Documented negative testing for HIV and hepatitis B Not at risk for HIV Study population balanced by Caucasian, African-American, Hispanic race. African American and Hispanic participants are currently needed. Age 18-50 years Able to meet study personnel on Anschutz Medical Campus for directly observed dosing with study medication, or by audio-visual communication with a mobile cellular device when off Campus
PI: Anderson, Peter
  • 303-724-8296
University of Colorado Recruiting Patients for a Clinical Research Study for Psoriasis 13-2720
The research study compares the effect of treatments, such as Humira and phototherapy, on inflammation in the body and cardiovascular disease. This study will look for systemic vascular inflammation in subjects enrolled in this study, with a test called FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography computed tomography).
We are looking for males and females 18 years of age and older with a diagnosis of psoriasis for at least 6 months
PI: Armstrong, April
  • 720-848-3607
Participate in a research study about body image dissatisfaction and psychosocial distress among breast cancer patients 15-0004
The purpose of this research study is to 1) determine the feasibility and impact of a 2 day body image workshop on breast cancer patients’ body image dissatisfaction, depression, and quality of life and 2) understand the relationships between body image, quality of life, and depression among patients with breast cancer.
Participants must be: 1) between the ages of 18-65, 2) histological or cytological confirmation of breast cancer (any clinical stage is allowed); 3) within 6 months of completion of surgery or final chemotherapy/radiation treatment for breast cancer, 4) experiencing concerns specific to body image.
PI: Pearson-Mauro , Adria
  • 720-251-4803
Exercise for Healthy Aging in HIV 14-2207
Determine the best “dose” of exercise in people aging with HIV, and whether or not the dose differs from people without HIV.
Men and women aged 50-70, on antiretroviral therapy for a minimum of 2 years with no detectable viral load, CD4 count >200; no active hepatitis C or hepatitis B; no major health problems that would interfere with the ability to exercise; if diabetic, must be well-controlled on oral medications (no insulin); body mass index between 20 and 40; no current/chronic infections besides HIV.
PI: Erlandson, MD, Kristine
  • 303-724-4941
Diabetic Male and Female Volunteers Needed for Exercise Research Study 06-0062
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
PI: Regensteiner, Judith
  • 303-724-2255
Trouble Controlling your Type 2 Diabetes? 12-1529
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
PI: Wyatt, Holly
  • GI Dynamics
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
PI: Booth, Robert
  • 1-800-429-9240
Persons with active, moderate to severe ulcerative colitis needed 12-1408
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
PI: Gerich, Mark
  • 303-724-7875
Have the Flu? Living with a chronic medical condition, too? 11-0101
Influenza (the flu) can be life-threatening. Approximately 24,000 people in the United States die each year of this disease. We are conducting a study to determine whether treating patients with a combination of several drugs instead of just one helps them to get better faster.
You qualify for our study if you: •Have been diagnosed with the flu •Are at least 18 years of age •Have an existing medical condition that puts you at increased risk for complications from the flu—conditions such as diabetes; heart, lung, and kidney disease; COPD; and asthma
PI: Barron, Michelle
  • 303-724-0712
Healthy Postmenopausal Women Needed for Cardiovascular Research Study 14-0532
The purpose of this study is to investigate how the health and function of arteries respond to estrogen, resveratrol, and exercise.
Postmenopausal women between the ages of 50-70 years, nonsmokers, not currently taking hormone replacement therapy or exercising vigorously more than 2 days per week.
PI: Moreau, Kerrie
  • 303-724-7465
Do you or someone you know have a food allergy to soy? 14-0097
We are studying the accuracy of a food allergy blood test.  
-Are age 1 to 21 and -Do have an IgE level greater than 0.35 to wheat OR soy or -Have had a positive skin test to wheat OR soy or -Have a clinically diagnosed wheat OR soy allergy -Do NOT use >500 micrograms/day fluticasone or equivalent -Do NOT have severe asthma, daily oral steroid dosing, or asthma requiring hospitalization within a year or an ER visit in the past 6 months -Do NOT have active EoE (or recently diagnosed) -Have NOT used biologic or allergen immunotherapy within the past year
PI: Fleischer, David
  • 720-777-2569
Participants Needed For Research on Military Veterans And Service Dogs 14-2041
The purpose of this study is to explore the relationship between military veterans and their service dogs. Veterans will participate in one on one interviews.
Are you a military veteran? Do you have a service dog? Are you 18-89 years old? If you answered yes to the above, contact C-P.A.W.W. today.
PI: Krause-Parello, Cheryl
  • (303)-724-8282

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
Page Size
 |  Displaying page 1 of 24, items 1 to 30 of 706.
Protocol TitlePI NameInstitution Number
Data pager
Page Size
 |  Displaying page 1 of 24, items 1 to 30 of 706.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo. Sponsor Protocol No. PM1116197. WIRB Protocol No. 20141040
Krantz, Mori14-1331
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy Sponsor Protocol No. 13-005 WIRB Protocol No. 20141141
Halbower, Ann14-1333
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects with Chronic Rhinosinusitis with Nasal Polyps. Sponsor Protocol No. 20110236. WIRB Protocol No. 20150667
Kingdom, Todd14-1371
An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment Sponsor Protocol No. D5160C00008 WIRB Protocol No. 20142209
O'Bryant, Cindy14-1390
Fleischer, David14-1399
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study Sponsor Protocol No. 191622-111 WIRB Protocol No. 20132162
Biffl, Susan14-1404
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study Protocol No. 191622-112 WIRB Protocol No. 20132135
Biffl, Susan14-1405
An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered with Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Sponsor Protocol No. M14-224. WIRB Protocol No. 20142269
Everson, Greg14-1435
A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma. Sponsor Protocol No. SAS115358. WIRB Protocol No. 20111924
Anderson, William14-1445
Gutman, Jonathan14-1455
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases Treated with Hormonal Treatment Background Therapy Sponsor Protocol No. BAY 88-8223 / 16298 WIRB Protocol No. 20150791
Fisher, Christine14-1465
Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors. Sponsor Protocol No. GO29313. WIRB Protocol No. 20141118
Camidge, David14-1476
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer. Sponsor Protocol No. M14-361. WIRB Protocol No. 20142537
Camidge, David14-1489
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II). Sponsor Protocol No. M14-868. WIRB Protocol No. 20141974
Everson, Greg14-1494
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection. Sponsor Protocol No. 2014-01. WIRB Protocol No. 20141261
Freeman, Stephen14-1538
Weekes, Colin14-1551
TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Sponsor Protocol No. CO-1686-022 WIRB Protocol No. 20142085
Camidge, David14-1569
An Open-Label, Multi-Center, 48-Week Study with a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy. Sponsor Protocol No. 4658-301-a1. WIRB Protocol No. 20141230
Parsons, Julie14-1629
Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma Sponsor Protocol No. PIN-PHO1201 WIRB Protocol No. 20140456
Shah, Raj14-1650
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease. Sponsor Protocol No. RECD3125. WIRB Protocol No. 20141667
Gerich, Mark14-1659
A Comparison of Soy Protein versus Soy-Dairy Protein-blend Containing Foods in the Colorado Diet for Weight loss and Maintenance. WIRB Protocol No. 20150081
Hill, James14-1666
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy Sponsor Protocol No. ALDOXORUBICIN-P2-SCLC-01 WIRB Protocol No. 20141373
Doebele, Robert14-1673

Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more